Bio-Rad Laboratories, Inc. $BIO Holdings Decreased by Kornitzer Capital Management Inc. KS

Kornitzer Capital Management Inc. KS decreased its holdings in shares of Bio-Rad Laboratories, Inc. (NYSE:BIO) by 31.3% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 6,606 shares of the medical research company’s stock after selling 3,010 shares during the quarter. Kornitzer Capital Management Inc. KS’s holdings in Bio-Rad Laboratories were worth $2,002,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds have also modified their holdings of BIO. Capital Research Global Investors purchased a new position in shares of Bio-Rad Laboratories during the third quarter valued at $117,303,000. Massachusetts Financial Services Co. MA grew its holdings in shares of Bio-Rad Laboratories by 4,534.4% during the fourth quarter. Massachusetts Financial Services Co. MA now owns 399,207 shares of the medical research company’s stock valued at $120,956,000 after buying an additional 390,593 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its holdings in shares of Bio-Rad Laboratories by 2,271.3% during the third quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 397,171 shares of the medical research company’s stock valued at $111,363,000 after buying an additional 380,422 shares in the last quarter. Mangrove Partners IM LLC purchased a new position in shares of Bio-Rad Laboratories during the third quarter valued at $35,568,000. Finally, Scopia Capital Management LP purchased a new position in shares of Bio-Rad Laboratories during the second quarter valued at $22,862,000. Hedge funds and other institutional investors own 65.24% of the company’s stock.

Bio-Rad Laboratories News Summary

Here are the key news stories impacting Bio-Rad Laboratories this week:

• Positive Sentiment: Revenue/operational positives — Q1 revenue of $592.1M slightly beat the consensus (~$590M) and revenue was up ~1.1% year?over?year; the company still shows a strong net margin (~29%). These factors provide some support versus a pure earnings shock. MarketBeat Q1 Release
• Neutral Sentiment: Analyst action — Wells Fargo cut its price target from $320 to $290 but kept an “equal weight” rating; the new PT still implies upside versus the current share level, which moderates the negative read on the name. Benzinga
• Neutral Sentiment: Full earnings call transcript now available — details on segment drivers, margin commentary and near?term cadence are in the call and may clarify management’s guidance changes for investors. Earnings Call Transcript
• Negative Sentiment: EPS miss — Q1 EPS was $1.89, below consensus (about $1.97) and down from $2.54 a year earlier, a clear earnings disappointment that weighed on sentiment. Zacks
• Negative Sentiment: Guidance cut — Management trimmed its FY?2026 outlook, issuing revenue guidance of about $2.5B–$2.6B versus consensus nearer the top of that range; the company explicitly lowered its outlook, which is the main driver of the share decline. TipRanks

Analyst Upgrades and Downgrades

BIO has been the topic of a number of research analyst reports. Wall Street Zen downgraded Bio-Rad Laboratories from a “buy” rating to a “hold” rating in a report on Saturday, February 14th. Citigroup downgraded Bio-Rad Laboratories from a “buy” rating to a “neutral” rating and lowered their price target for the company from $375.00 to $300.00 in a report on Tuesday, April 7th. Finally, Wells Fargo & Company reduced their price objective on Bio-Rad Laboratories from $320.00 to $290.00 and set an “equal weight” rating for the company in a research report on Friday. One research analyst has rated the stock with a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, Bio-Rad Laboratories has a consensus rating of “Hold” and an average price target of $333.00.

Bio-Rad Laboratories Price Performance

Shares of NYSE:BIO opened at $255.70 on Monday. Bio-Rad Laboratories, Inc. has a fifty-two week low of $211.43 and a fifty-two week high of $343.12. The business has a 50-day moving average of $277.81 and a two-hundred day moving average of $298.11. The stock has a market capitalization of $6.90 billion, a P/E ratio of 42.12 and a beta of 1.06. The company has a debt-to-equity ratio of 0.12, a current ratio of 3.21 and a quick ratio of 2.37.

Bio-Rad Laboratories (NYSE:BIO) last announced its quarterly earnings results on Thursday, April 30th. The medical research company reported $1.89 earnings per share for the quarter, missing analysts’ consensus estimates of $1.97 by ($0.08). Bio-Rad Laboratories had a return on equity of 3.56% and a net margin of 6.52%.The company had revenue of $592.10 million during the quarter, compared to analyst estimates of $589.91 million. During the same period in the prior year, the firm earned $2.54 EPS. Bio-Rad Laboratories’s quarterly revenue was up 1.1% on a year-over-year basis. On average, equities research analysts predict that Bio-Rad Laboratories, Inc. will post 10.32 EPS for the current fiscal year.

Bio-Rad Laboratories Company Profile

Bio-Rad Laboratories, Inc is a global provider of life science research and clinical diagnostic products. The company operates through two primary business segments: Life Science and Clinical Diagnostics. Within the Life Science segment, Bio-Rad offers instruments, reagents and consumables for protein analysis, cell biology, gene expression and other molecular biology applications. The Clinical Diagnostics segment supplies quality control products, blood-typing reagents and instruments, and molecular diagnostic assays used in blood screening, infectious disease testing and routine clinical laboratories.

Founded in 1952 by David and Alice Schwartz and headquartered in Hercules, California, Bio-Rad has grown its footprint across the Americas, Europe, Asia-Pacific and other regions.